Company news
Immuneering Corporation news in 2024
Immuneering Corporation's news releases, calls and decks from 2024, newest first.
Immuneering Launches Pancreatic Cancer Advisory Board
December 18, 2024
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
December 11, 2024
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 12, 2024
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 14, 2024
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
September 11, 2024
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 5, 2024
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
July 30, 2024
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
May 6, 2024
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
March 26, 2024
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
March 13, 2024
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
March 11, 2024
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
March 10, 2024
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
February 29, 2024
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
February 19, 2024
Immuneering Announces Participation in February Investor Conferences
January 31, 2024